COMP <GO>
GALT vs CTNM // EV/EBITDA & P/E VALUATION
Galectin Therapeutics Inc. (NASDAQ) VS. Contineum Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: GALT 3
— CTNM 2
■ METRIC PARITY
LAST: $3.52 (-0.56%) • MKT CAP: $355.8M
valuation
—
LAST: $9.33 (+1.97%) • MKT CAP: $351.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GALT VS. CTNM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GALT | CTNM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -29.00% | -6.00 | CTNM | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.71% | -15.82% | +9.11 | GALT | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | GALT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.7 | 43.0 | -2.38 | CTNM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $355.8M | $351.0M | $4.8M | GALT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GALT REV | CTNM REV | GALT GROSS % | CTNM GROSS % | GALT FCF | CTNM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$23.9M | -$55.5M |
| FY 2024 | $0 | $0 | — | — | -$41.8M | -$33.4M |
| FY 2023 | $0 | $50.0M | — | — | -$33.0M | $19.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GALT // BETA —
CTNM // BETA —